会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • MESALAMINE SUPPOSITORY
    • 木脂素支架
    • US20090022793A1
    • 2009-01-22
    • US12245648
    • 2008-10-03
    • Carl GauthierYves DumoulinDavid Powell
    • Carl GauthierYves DumoulinDavid Powell
    • A61K9/20A61K31/137
    • A61K9/02A61K31/137A61K47/44Y10S514/953
    • The present invention relates to a mesalamine rectal suppository designed to provide improved comfort of use. One embodiment of the invention is a mesalamine rectal suppository comprising mesalamine and one or more pharmaceutically acceptable excipients, wherein the drug load of the suppository ranges from 35% to 50%. Another embodiment of the invention is a mesalamine rectal suppository comprising from about 850 to about 1150 mg mesalamine and one or more pharmaceutically acceptable excipients, wherein the total weight of the suppository ranges from about 2250 to about 2700 mg. Yet another embodiment of the invention is a mesalamine rectal suppository comprising mesalamine having a tap density ranging from about 600 to about 800 g/L (as measured by USP ) and a hard fat having an ascending melting point of 32 to 35.5° C. Methods of preparing and methods of treatment with mesalamine suppositories are also provided. The invention further provides a method of determining a dissolution parameter (such as dissolution rate) of a mesalamine rectal suppository, such as a 1 g mesalamine suppository, by measuring its dissolution with USP Apparatus #2 at 40° C. and a paddle rotation speed of 125 rpm in 0.2 M phosphate buffer at a pH of 7.5.
    • 本发明涉及美沙拉坦直肠栓剂,其旨在提供改善的使用舒适性。 本发明的一个实施方案是美沙拉坦直肠栓剂,其包含美沙拉嗪和一种或多种药学上可接受的赋形剂,其中栓剂的药物负载范围为35%至50%。 本发明的另一个实施方案是美沙拉坦直肠栓剂,其包含约850至约1150mg美沙拉嗪和一种或多种药学上可接受的赋形剂,其中栓剂的总重量为约2250至约2700mg。 本发明的另一个实施方案是美沙拉坦直肠栓剂,其包含振荡密度范围为约600至约800g / L的美沙拉嗪(通过USP <616>测量)和具有上升熔点为32至35.5°的硬脂肪 C.还提供了制备方法和美沙拉嗪栓剂的治疗方法。 本发明还提供了一种通过用USP装置#2在40℃下测量溶解参数(例如溶解度)来测定美沙拉嗪直肠栓剂如1g美沙胺栓剂的溶出参数(如溶出速率),并且桨叶转速 在pH 7.5的0.2M磷酸盐缓冲液中的125rpm。
    • 2. 发明授权
    • Mesalamine suppository
    • 美沙胺栓剂
    • US08436051B2
    • 2013-05-07
    • US12639645
    • 2009-12-16
    • Carl GauthierYves DumoulinDavid PowellHugues Moreau
    • Carl GauthierYves DumoulinDavid PowellHugues Moreau
    • A01N33/02A01N37/36A01N37/12A01N37/44A61K31/135A61K31/60A61K31/195A61F13/00
    • A61K9/14A61K9/0031A61K9/02A61K31/136A61K31/195A61K31/606A61K47/44
    • The present invention relates to a mesalamine rectal suppository designed to provide improved comfort of use. One embodiment of the invention is a mesalamine rectal suppository comprising mesalamine and one or more pharmaceutically acceptable excipients, wherein the drug load of the suppository ranges from 35% to 50%. Yet another embodiment of the invention is a mesalamine rectal suppository comprising mesalamine having a tap density ranging from about 600 to about 800 g/L (as measured by USP ) and a hard fat having an ascending melting point of 32 to 35.5° C. Yet another embodiment is a mesalamine rectal suppository comprising mesalamine particles and one or more pharmaceutically acceptable excipients, where the mesalamine particles have a surface area of from about 0.1 m2/g to about 2.8 m2/g (e.g., from about 0.1 m2/g to about 1.3 m2/g). Methods of preparing and methods of treatment with mesalamine suppositories are also provided. The invention further provides a method of determining a dissolution parameter (such as dissolution rate) of a mesalamine rectal suppository, such as a 1 g mesalamine suppository, by measuring its dissolution with USP Apparatus #2 at 40° C. and a paddle rotation speed of 125 rpm in 0.2 M phosphate buffer at a pH of 7.5.
    • 本发明涉及美沙拉坦直肠栓剂,其旨在提供改善的使用舒适性。 本发明的一个实施方案是美沙拉坦直肠栓剂,其包含美沙拉嗪和一种或多种药学上可接受的赋形剂,其中栓剂的药物负载范围为35%至50%。 本发明的另一个实施方案是美沙拉坦直肠栓剂,其包含振荡密度范围为约600至约800g / L的美沙拉嗪(通过USP <616>测量)和具有上升熔点为32至35.5°的硬脂肪 C.另一个实施方案是美沙拉坦直肠栓剂,其包含美沙拉嗪颗粒和一种或多种药学上可接受的赋形剂,其中美沙拉嗪颗粒的表面积为约0.1m 2 / g至约2.8m 2 / g(例如,约0.1m 2 / g至约1.3m 2 / g)。 还提供了制备方法和美沙拉坦栓剂的治疗方法。 本发明还提供了一种通过用USP装置#2在40℃下测量溶解参数(例如溶解度)来测定美沙拉嗪直肠栓剂如1g美沙胺栓剂的溶出参数(如溶出速率),并且桨叶转速 在pH 7.5的0.2M磷酸盐缓冲液中的125rpm。
    • 3. 发明授权
    • Mesalamine suppository
    • 美沙胺栓剂
    • US07541384B2
    • 2009-06-02
    • US12245648
    • 2008-10-03
    • Carl GauthierYves DumoulinDavid Powell
    • Carl GauthierYves DumoulinDavid Powell
    • A01N33/02A01N37/36A01N37/12A01N37/44A61K31/135A61K31/60A61K31/195A61F13/00
    • A61K9/02A61K31/137A61K47/44Y10S514/953
    • The present invention relates to a mesalamine rectal suppository designed to provide improved comfort of use. One embodiment of the invention is a mesalamine rectal suppository containing mesalamine and one or more pharmaceutically acceptable excipients, wherein the drug load of the suppository ranges from 35% to 50%. Another embodiment of the invention is a mesalamine rectal suppository containing from about 850 to about 1150 mg mesalamine and one or more pharmaceutically acceptable excipients, wherein the total weight of the suppository ranges from about 2250 to about 2700 mg. Yet another embodiment of the invention is a mesalamine rectal suppository comprising mesalamine having a tap density ranging from about 600 to about 800 g/L (as measured by USP ) and a hard fat having an ascending melting point of 32 to 35.5° C. Methods of preparing and methods of treatment with mesalamine suppositories are also provided. The invention further provides a method of determining a dissolution parameter (such as dissolution rate) of a mesalamine rectal suppository, such as a 1 g mesalamine suppository, by measuring its dissolution with USP Apparatus #2 at 40° C. and a paddle rotation speed of 125 rpm in 0.2 M phosphate buffer at a pH of 7.5.
    • 本发明涉及美沙拉坦直肠栓剂,其旨在提供改善的使用舒适性。 本发明的一个实施方案是美沙拉坦直肠栓剂,其含有美沙拉嗪和一种或多种药学上可接受的赋形剂,其中栓剂的药物负载范围为35%至50%。 本发明的另一个实施方案是含有约850至约1150mg美沙拉嗪和一种或多种药学上可接受的赋形剂的美沙拉嗪直肠栓剂,其中栓剂的总重量为约2250至约2700mg。 本发明的另一个实施方案是美沙拉坦直肠栓剂,其包含振荡密度范围为约600至约800g / L的美沙拉嗪(通过USP <616>测量)和具有上升熔点为32至35.5°的硬脂肪 C.还提供了制备方法和美沙拉嗪栓剂的治疗方法。 本发明还提供了一种通过用USP装置#2在40℃下测量溶解参数(例如溶解度)来测定美沙拉嗪直肠栓剂如1g美沙胺栓剂的溶出参数(如溶出速率),并且桨叶转速 在pH 7.5的0.2M磷酸盐缓冲液中的125rpm。
    • 4. 发明授权
    • Mesalamine suppository
    • 美沙胺栓剂
    • US08217083B2
    • 2012-07-10
    • US12476185
    • 2009-06-01
    • Carl GauthierYves DumoulinDavid Powell
    • Carl GauthierYves DumoulinDavid Powell
    • A01N33/02A01N37/36A01N37/12A01N37/44A61K31/135A61K31/60A61K31/195A61F13/00
    • A61K9/02A61K31/137A61K47/44Y10S514/953
    • The present invention relates to a mesalamine rectal suppository designed to provide improved comfort of use. One embodiment of the invention is a mesalamine rectal suppository comprising mesalamine and one or more pharmaceutically acceptable excipients, wherein the drug load of the suppository ranges from 35% to 50%. Another embodiment of the invention is a mesalamine rectal suppository comprising from about 850 to about 1150 mg mesalamine and one or more pharmaceutically acceptable excipients, wherein the total weight of the suppository ranges from about 2250 to about 2700 mg. Another embodiment of the invention is a mesalamine rectal suppository comprising from about 400 to about 600 mg mesalamine and one or more pharmaceutically acceptable excipients, wherein the total weight of the suppository ranges from about 870 to about 1715 mg. Yet another embodiment of the invention is a mesalamine rectal suppository comprising mesalamine having a tap density ranging from about 600 to about 800 g/L (as measured by USP ) and a hard fat having an ascending melting point of 32 to 35.5° C. Methods of preparing and methods of treatment with mesalamine suppositories are also provided. The invention further provides a method of determining a dissolution parameter (such as dissolution rate) of a mesalamine rectal suppository, such as a 1 g mesalamine suppository, by measuring its dissolution with USP Apparatus #2 at 40° C. and a paddle rotation speed of 125 rpm in 0.2 M phosphate buffer at a pH of 7.5.
    • 本发明涉及美沙拉坦直肠栓剂,其旨在提供改善的使用舒适性。 本发明的一个实施方案是美沙拉坦直肠栓剂,其包含美沙拉嗪和一种或多种药学上可接受的赋形剂,其中栓剂的药物负载范围为35%至50%。 本发明的另一个实施方案是美沙拉坦直肠栓剂,其包含约850至约1150mg美沙拉嗪和一种或多种药学上可接受的赋形剂,其中栓剂的总重量为约2250至约2700mg。 本发明的另一个实施方案是美沙拉坦直肠栓剂,其包含约400至约600mg的美沙拉嗪和一种或多种药学上可接受的赋形剂,其中栓剂的总重量为约870至约1715mg。 本发明的另一个实施方案是美沙拉坦直肠栓剂,其包含振荡密度范围为约600至约800g / L的美沙拉嗪(通过USP <616>测量)和具有上升熔点为32至35.5°的硬脂肪 C.还提供了制备方法和美沙拉嗪栓剂的治疗方法。 本发明还提供了一种通过用USP装置#2在40℃下测量溶解参数(例如溶解度)来测定美沙拉嗪直肠栓剂如1g美沙胺栓剂的溶出参数(如溶出速率),并且桨叶转速 在pH 7.5的0.2M磷酸盐缓冲液中的125rpm。
    • 5. 发明申请
    • MESALAMINE SUPPOSITORY
    • 木脂素支架
    • US20100105639A1
    • 2010-04-29
    • US12639645
    • 2009-12-16
    • Yves DumoulinCarl GauthierDavid PowellHugues Moreau
    • Yves DumoulinCarl GauthierDavid PowellHugues Moreau
    • A61K31/606A61P1/00
    • A61K9/14A61K9/0031A61K9/02A61K31/136A61K31/195A61K31/606A61K47/44
    • The present invention relates to a mesalamine rectal suppository designed to provide improved comfort of use. One embodiment of the invention is a mesalamine rectal suppository comprising mesalamine and one or more pharmaceutically acceptable excipients, wherein the drug load of the suppository ranges from 35% to 50%. Yet another embodiment of the invention is a mesalamine rectal suppository comprising mesalamine having a tap density ranging from about 600 to about 800 g/L (as measured by USP ) and a hard fat having an ascending melting point of 32 to 35.5° C. Yet another embodiment is a mesalamine rectal suppository comprising mesalamine particles and one or more pharmaceutically acceptable excipients, where the mesalamine particles have a surface area of from about 0.1 m2/g to about 2.8 m2/g (e.g., from about 0.1 m2/g to about 1.3 m2/g). Methods of preparing and methods of treatment with mesalamine suppositories are also provided. The invention further provides a method of determining a dissolution parameter (such as dissolution rate) of a mesalamine rectal suppository, such as a 1 g mesalamine suppository, by measuring its dissolution with USP Apparatus #2 at 40° C. and a paddle rotation speed of 125 rpm in 0.2 M phosphate buffer at a pH of 7.5.
    • 本发明涉及美沙拉坦直肠栓剂,其旨在提供改善的使用舒适性。 本发明的一个实施方案是美沙拉坦直肠栓剂,其包含美沙拉嗪和一种或多种药学上可接受的赋形剂,其中栓剂的药物负载范围为35%至50%。 本发明的另一个实施方案是美沙拉坦直肠栓剂,其包含振荡密度范围为约600至约800g / L的美沙拉嗪(通过USP <616>测量)和具有上升熔点为32至35.5°的硬脂肪 C.另一个实施方案是美沙拉坦直肠栓剂,其包含美沙拉嗪颗粒和一种或多种药学上可接受的赋形剂,其中美沙拉嗪颗粒的表面积为约0.1m 2 / g至约2.8m 2 / g(例如,约0.1m 2 / g至约1.3m 2 / g)。 还提供了制备方法和美沙拉坦栓剂的治疗方法。 本发明还提供了一种通过用USP装置#2在40℃下测量溶解参数(例如溶解度)来测定美沙拉嗪直肠栓剂如1g美沙胺栓剂的溶出参数(如溶出速率),并且桨叶转速 在pH 7.5的0.2M磷酸盐缓冲液中的125rpm。
    • 6. 发明申请
    • MESALAMINE SUPPOSITORY
    • 木脂素支架
    • US20090264386A1
    • 2009-10-22
    • US12476185
    • 2009-06-01
    • Carl GauthierYves DumoulinDavid Powell
    • Carl GauthierYves DumoulinDavid Powell
    • A61K31/606A61P1/00
    • A61K9/02A61K31/137A61K47/44Y10S514/953
    • The present invention relates to a mesalamine rectal suppository designed to provide improved comfort of use. One embodiment of the invention is a mesalamine rectal suppository comprising mesalamine and one or more pharmaceutically acceptable excipients, wherein the drug load of the suppository ranges from 35% to 50%. Another embodiment of the invention is a mesalamine rectal suppository comprising from about 850 to about 1150 mg mesalamine and one or more pharmaceutically acceptable excipients, wherein the total weight of the suppository ranges from about 2250 to about 2700 mg. Another embodiment of the invention is a mesalamine rectal suppository comprising from about 400 to about 600 mg mesalamine and one or more pharmaceutically acceptable excipients, wherein the total weight of the suppository ranges from about 870 to about 1715 mg. Yet another embodiment of the invention is a mesalamine rectal suppository comprising mesalamine having a tap density ranging from about 600 to about 800 g/L (as measured by USP ) and a hard fat having an ascending melting point of 32 to 35.5° C. Methods of preparing and methods of treatment with mesalamine suppositories are also provided. The invention further provides a method of determining a dissolution parameter (such as dissolution rate) of a mesalamine rectal suppository, such as a 1 g mesalamine suppository, by measuring its dissolution with USP Apparatus #2 at 40° C. and a paddle rotation speed of 125 rpm in 0.2 M phosphate buffer at a pH of 7.5.
    • 本发明涉及美沙拉坦直肠栓剂,其旨在提供改善的使用舒适性。 本发明的一个实施方案是美沙拉坦直肠栓剂,其包含美沙拉嗪和一种或多种药学上可接受的赋形剂,其中栓剂的药物负载范围为35%至50%。 本发明的另一个实施方案是美沙拉坦直肠栓剂,其包含约850至约1150mg美沙拉嗪和一种或多种药学上可接受的赋形剂,其中栓剂的总重量为约2250至约2700mg。 本发明的另一个实施方案是美沙拉坦直肠栓剂,其包含约400至约600mg的美沙拉嗪和一种或多种药学上可接受的赋形剂,其中栓剂的总重量为约870至约1715mg。 本发明的另一个实施方案是美沙拉坦直肠栓剂,其包含振荡密度范围为约600至约800g / L的美沙拉嗪(通过USP <616>测量)和具有上升熔点为32至35.5°的硬脂肪 C.还提供了制备方法和美沙拉嗪栓剂的治疗方法。 本发明还提供了一种通过用USP装置#2在40℃下测量溶解参数(例如溶解度)来测定美沙拉嗪直肠栓剂如1g美沙胺栓剂的溶出参数(如溶出速率),并且桨叶转速 在pH 7.5的0.2M磷酸盐缓冲液中的125rpm。